Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Suffers from a major depressive episode recurrent as the primary diagnosis according to the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria.~* Has a Montgomery Åsberg Depression Rating Scale (MADRS) total score of 26 or greater at Screening and Baseline Visits.~* Has a Clinical Global Impression - Severity of Illness (CGI-S) score of 4 or greater at Screening and Baseline Visits.~Exclusion Criteria:~* Has previously participated in a Lu AA21004 clinical study.~* Has 1 or more the following:~  * Any current psychiatric disorder other than Major Depressive Disorder as defined in the DSM-IV~ * Current or past history of: manic or hypomanic episode, schizophrenia or any other psychotic disorder defined in the DSM-IV-TR.~ * Diagnosis of alcohol or other substance disorder (except nicotine and caffeine) as defined in the DSM-IV-TR that has not been in sustained full remission for at least years prior to screening (participant must also have negative urine drug screen prior to Baseline).~ * Presence or history of a clinically significant neurological disorder (including epilepsy)~ * Neurodegenerative disorder.~ * Any Axis II disorder that might compromise the study.~* Has a thyroid stimulating hormone value outside the normal range at the Screening Visit that is deemed clinically significant by the investigator.~* Has clinically significant abnormal vital signs as determined by the investigator.~* Has an abnormal Electrocardiogram.~* Has an alanine aminotransferase, aspartate aminotransferase or total bilirubin level greater than 1.5 times the upper limits of normal.~* Has a previous history of cancer that had been in remission for less than 5 years prior to the first dose of study medication.~* Has a disease or takes medication that, in the opinion of the investigator, could interfere with the assessments of safety, tolerability, or efficacy.~* Has a known history of or currently has increased intraocular pressure or is at risk of acute narrow-angle glaucoma.~* Has a clinically significant unstable illness, for example, hepatic impairment or renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, rheumatologic, immunologic, infectious, skin and subcutaneous tissue disorders, or metabolic disturbance. For the purposes of this protocol the following conditions are considered unstable due to the potential impact on assessment of MDD response: pain disorder, chronic fatigue syndrome, fibromyalgia, and obstructive sleep apnea.~* Has a significant risk of suicide according to the investigator's opinion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo-matching capsules, orally, once daily for up to 8 weeks.
- Vortioxetine 10 mg (Type: EXPERIMENTAL): Vortioxetine 10 mg, encapsulated tablets, orally, once daily for up to 8 weeks.
- Vortioxetine 20 mg (Type: EXPERIMENTAL): Vortioxetine 10 mg, encapsulated tablets, orally, once daily for one week then vortioxetine 20 mg, encapsulated tablets, orally, once daily for up to 7 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete